Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
10x Genomics Inc (TXG)
NASDAQ:TXG
10x Genomics (TXG) Stock Price & Analysis
809 Followers
TXG Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$15.28 - $63.57
Previous Close$17.49
Volume1.93M
Average Volume (3M)1.85M
Market Cap
$2.09B
Enterprise Value$1.81B
Total Cash (Recent Filing)$371.81M
Total Debt (Recent Filing)$92.18M
Price to Earnings (P/E)―
Beta2.52
Next Earnings
Aug 08, 2024EPS Estimate
-$0.48Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.24
Shares Outstanding119,708,426
10 Day Avg. Volume1,124,596
30 Day Avg. Volume1,853,169
Standard Deviation0.17
R-Squared0.34
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)3.37
Price to Sales (P/S)11.28
Price to Cash Flow (P/CF)-37.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.90
Enterprise Value/Gross Profit4.43
Enterprise Value/Ebitda-8.62
Forecast
1Y Price Target
$34.55Price Target Upside99.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
10x Genomics News
PremiumCompany Announcements
10x Genomics Welcomes Sarah Teichmann to Board
Bulls Say, Bears Say
Bulls Say
Customer InterestSpatial products, particularly Xenium, continue to ramp well and generate customer interest.
Product LaunchesRecent launches show the R&D engine is intact.
Technology LeadershipIndustry participants acknowledged 10x as both the leader in single cell and spatial technology citing ease-of-use, field service, and technical support.
Bears Say
CompetitionIllumina's acquisition of private single cell peer Fluent heightens the competitive threat.
Financial PerformanceChromium consumables declined by 17% year-over-year.
Market DynamicsChromium's high cost is cited as the greatest barrier to adoption or to increasing the number of samples.
---
Ownership Overview
17.85% Insiders
34.06% Mutual Funds
21.05% Other Institutional Investors
27.04% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TXG FAQ
What was 10x Genomics Inc’s price range in the past 12 months?
10x Genomics Inc lowest stock price was $15.28 and its highest was $63.57 in the past 12 months.
What is 10x Genomics Inc’s market cap?
Currently, no data Available
When is 10x Genomics Inc’s upcoming earnings report date?
10x Genomics Inc’s upcoming earnings report date is Aug 08, 2024 which is in 23 days.
How were 10x Genomics Inc’s earnings last quarter?
10x Genomics Inc released its earnings results on Apr 30, 2024. The company reported -$0.5 earnings per share for the quarter, the consensus estimate of -$0.5 by $0.
Is 10x Genomics Inc overvalued?
According to Wall Street analysts 10x Genomics Inc’s price is currently Undervalued.
Does 10x Genomics Inc pay dividends?
10x Genomics Inc does not currently pay dividends.
What is 10x Genomics Inc’s EPS estimate?
10x Genomics Inc’s EPS estimate is -$0.48.
How many shares outstanding does 10x Genomics Inc have?
10x Genomics Inc has 105,651,596 shares outstanding.
What happened to 10x Genomics Inc’s price movement after its last earnings report?
10x Genomics Inc reported an EPS of -$0.5 in its last earnings report, expectations of -$0.5. Following the earnings report the stock price went down -8.06%.
Which hedge fund is a major shareholder of 10x Genomics Inc?
Among the largest hedge funds holding 10x Genomics Inc’s share is ARK Investment Management LLC. It holds 10x Genomics Inc’s shares valued at 236M.
---
10x Genomics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$34.55 (99.48% Upside)
$34.55 (99.48% Upside)
Blogger Sentiment
Bullish
TXG Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 1.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $217.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.7%
Last 30 Days ▲ 10.7%
Last 30 Days ▲ 10.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-70.62%
12-Months-Change
Fundamentals
Return on Equity
-34.75%
Trailing 12-Months
Asset Growth
-8.99%
Trailing 12-Months
Company Description
10x Genomics Inc
10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell transcriptomics, single cell genomics, single cell epigenomes, linked-reads genomics and spatial transcriptomics. The company's products include Single Cell Gene Expression, Immune Profiling, CNV, ATAC, and Genome and Exome. 10X Genomics was founded by Serge Saxonov, Ben Hindson, Kevin D. Ness and Eduard Diviu Terradas on July 2, 2012 and is headquartered in Pleasanton, CA.
---
TXG Earnings Call
Q1 2024
0:00 / 0:00
---
TXG Revenue Breakdown
77.51% Consumables
19.96% Instruments
2.54% Services
---
TXG Stock 12 Month Forecast
Average Price Target
$34.55
▲(99.48% Upside)
Technical Analysis
Best Analysts Covering TXG
1 Year
1 Year Success Rate
6/12 ratings generated profit
1 Year Average Return
-9.02%
reiterated a buy rating 3 months ago
Copying Tejas Savant's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -9.02% per trade.
---